CAD Flashcards

1
Q

Metabolic syndrome

A
3/5 criteria
Abdominal obesity (>= 102 cm men, >= 88 cm in men)
TG > 175
HDL < 40 men, < 50 women
BP > 130/85
Fasting glucose >= 100
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Indication for stress EKG in asymptomatic

A

CLass IIb

Intermediate risk, particularly when starting exercise program

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Indication for asymptomatic stress test with imaging

A

May be considered when DM, strong FH CHD, previous assessment suggests high risk such as CAC score > 400

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Very high risk ASCVD

A

History of ASCVD

>= 2 events or 1 events and >=2 conditions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Events for ACSVD very high risk

A

ACS < 12 mo
h/o MI or stroke
Symptomatic PAD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Conditions for ASCVD very high risk

A
Smoker, DM, HTN
LDL >= 100 on max therapy
>= 65
Heterozygous FH
h/o CABG or PCI
CKD GFR 15-59
CHF
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Very high risk ASCVD LDL goal

A

<70

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

History of ASCVD, not very high risk LDL goal

A

Lower by 50%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

LDL >= 190, primary prevention goal

A

Lower by 50% or LDL < 100

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

DM + ASCVD risk > 20% treatment

A

High intensity statin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

DM + ASCVD risk < 20% treatment

A

Look at risk enhancers
If yes -> high intensity
If not -> moderate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

DM risk enhancers for primary prevention

A
DM2 for 10 yrs, DM1 for 20 yrs
Ur albumin >= 30 mcg/mg creat
eGFR < 60
Retinopathy, neuropathy
ABI < 0.9
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

LDL < 190, non-DM management age 0-19

A

Lifestyle

Statin if FH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

LDL < 190, non-DM management age 20-39

A

Lifestyle

If early ASCVD and LDL > 160 -> statin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

LDL < 190, non-DM management age 40-75

A

Risk calculator

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

ASCVD risk >= 20% treatment

A

High intensity statin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

ASCVD risk <= 5%

A

Lifestyle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

ASCVD risk 5-20% treatment

A

Borderline, look at risk enhancers
If yes -> moderate statin
If uncertain and 7.5-20 -> CAC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

High intensity statin reduction

A

> =50%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Moderate intensity statin reduction

A

30-50%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Low intensity statin reduction

A

<30%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Aspirin primary prevention indication

A

Class IIb

ASCVD > 20%, maybe >10%, not increased bleeding risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Duke treadmill score

A

Maximum exercise time in minutes - 5(ST segment deviation in mm) - 4(angina index)

24
Q

High risk duke treadmill score

25
Low risk duke treadmill score
>= 5
26
Class I for coronary angiography
High likelihood of severe CAD | Unacceptable symptoms despite GDMT
27
High risk CAD (>3% risk of death or MI / year) at rest
EF < 35% >10% myocardium perfusion abnormality without prior history or evidence of MI Multivessel disease or LM 50% on CCTA
28
High risk CAD (>3% risk of death or MI / year) on stress
>= 2 mm ST depression on stress EKG Stress induced LV dysfunction (EF < 45 or drop 10) 10% myocardium or multiple territory induced perfusion abn Stress induced LV dilatation Induced WMA >2 seg or 2 coronary beds WMA at low dose of dobutmaine <10 or HR <= 120
29
AUC for coronary angiography
- Symptomatic with high pretest probability of CAD without stress test - Intermediate risk stress imaging - Discordant clinical and stress result - Equivocal / non-diagnostic stress - CCTA: symptomatic with >= 50% / possibly obstructive stenosis
30
Class I for CABG in SIHD, improves survival
Left main 3VD 2VD with proximal LAD Post arrest with ischemia mediated VT
31
Class IIa CABG in SIHD
1 vessel with proximal LAD
32
Class IIa for FFR in SIHD
Intermediate lesions 50-70%
33
Class I for PCI in SIHD
1+ significant stenosis, unacceptable angina despite GDMT (excluding improved survival with CABG)
34
Low SYNTAX score
0-22
35
Intermediate SYNTAX score
23-32
36
High SYNTAX score
>33
37
Class IIa LM PCI in SIHD
Low risk SYNTAX | STS >= 5%
38
LM in SIHD treatment
``` CABG for most PCI in low risk and complexity class IIa ```
39
3VD in SIHD treatment
CABG for most | PCI if low risk, SYNTAX <= 22, non-DM
40
2VD in SIHD treatment
PCI or CABG
41
1VD in SIHD treatment
PCI
42
High risk MPI stress findings
- >12% myocardial defect - Severe reversible defect - Abnormal EF - Increased lung uptake of tracer - Transient ischemic dilation (TID)
43
Duke treadmill score
Exercise duration (minutes) - (4 x angina index) - (5 x maximum ST deviation)
44
Angina index
0 - no angina 1 - angina that doesn't limit exercise 2 - angina limiting exercise
45
Low risk DTS
>= 5 | 5 year survival 97%
46
Intermediate risk DTS
-10 to +4 | 90% 5 year survival
47
High risk DTS
-11 or lower | 65% 5 year survival
48
Strongest predictors of post-STEMI mortality
Age > 75 | SBP < 100
49
Carotid duplex before CABG if
``` >65 L main PAD Smoking Stroke/TIA Carotid bruit ```
50
Coronary flow reserve
For microvascular dysfunction | Ratio of intracoronary mean velocity with hyperemia / baseline
51
CFR response to IC adenosine < 2.5
non-endothelial microvascular dysfunction
52
CFR decreased coronary diameter in response to IC acetylcholine
macrovascular dysfunction 
53
CFR increased coronary diameter in response to IC NG
non endothelial macrovascular dysfunction
54
Atheroembolic embolization / cholesterol emboli
livedo reticularis, eosinophils in urine with renal dysfunction
55
Cholesterol emboli management
Aggressive secondary prevention